Article
NovoEight Shown to Reduce Annualized Bleeding Rate Among Patients with Hemophilia A
Author(s):
Novo Nordisk announced that its phase 3 study of patients with hemophilia A, who had the highest annualized bleeding rates in its previous study, saw the biggest reduction in bleeding over the duration of treatment using turoctocog alfa.
Novo Nordisk announced that its phase 3 study of patients with hemophilia A, who had the highest annualized bleeding rates (ABR) in its previous study, saw the biggest reduction in bleeding over the duration of treatment using turoctocog alfa (NovoEight).
Adult and adolescent patients with hemophilia A who continued NovoEight treatment also saw reductions of 69% and 63%, respectively, in ABRs compared with their ABRs from Novo Nordisk’s first study of patients taking NovoEight to treat hemophilia A.
“This post hoc analysis gives an indication that patients with high baseline bleed rate can benefit from prophylaxis with NovoEight, as well as patients who maintain low ABR,” said Margareth Ozelo, MD, PhD, Hemocentre, IHTC, University of Campinas, Sao Paulo, Brazil, and lead investigator, in a press release.
The most common side effects were injection site reactions, increased hepatic enzymes, and fever, according to Novo Nordisk.
Hemophilia, which interferes with an individual’s ability to create blood clots properly, affects more than 400,000 people worldwide.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
